IRB Audit Findings: Common Issues in Clinical Trials

Posted on September 3, 2025 By digi

Published on 25/12/2025

Understanding Common IRB Audit Findings in Clinical Trials

Table of Contents

Toggle

Introduction: The Role of IRBs in Clinical Trials

Institutional Review Boards (IRBs) or Ethics Committees (ECs) play a critical role in protecting the rights, safety, and welfare of participants in clinical trials. Regulatory agencies such as the FDA, EMA, and MHRA require IRBs to ensure that trials comply with ethical and scientific standards under ICH GCP. Despite their importance, IRBs frequently appear in regulatory audit reports with recurring deficiencies.

Common IRB audit findings include delays in protocol approvals, incomplete review documentation, poor oversight of ongoing studies, and inadequate handling of Serious Adverse Events (SAEs). These issues undermine trial integrity and expose sponsors and investigators to compliance risks.

Regulatory Expectations for IRBs

Authorities have set specific expectations for IRBs to ensure compliance:

• Review and approve all trial protocols and amendments before implementation.
• Ensure informed consent documents are compliant, accurate, and approved before use.
• Review safety data, including SAEs and SUSARs, in a timely manner.
• Maintain detailed minutes of IRB meetings and decisions.
• Conduct continuing

Continue Reading

review of ongoing studies at least annually.

The ClinicalTrials.gov registry underscores the role of IRBs in ensuring transparency and ethical oversight in clinical research.

Common IRB Audit Findings in Clinical Trials

1. Delayed Protocol Approvals

Auditors frequently cite IRBs for approving protocols or amendments after trial activities have already started.

2. Incomplete Documentation of Reviews

Inspection reports often highlight missing IRB approval letters or inadequate documentation of meeting deliberations.

3. Failure to Conduct Continuing Review

Auditors commonly note lapses in annual reviews of ongoing trials, a clear non-compliance with ICH GCP.

4. Inadequate SAE Oversight

IRBs are often cited for failing to review SAE or SUSAR reports promptly and comprehensively.

Case Study: FDA Audit on IRB Deficiencies

During an FDA inspection of a Phase II oncology trial, inspectors noted that the IRB failed to review continuing safety reports for over a year. Several amendments were also implemented without prior IRB approval. The FDA classified this as a major deficiency, requiring corrective action by both the sponsor and the IRB.

Root Causes of IRB Audit Findings

Root cause analysis of common IRB audit findings often reveals:

• Resource limitations leading to delayed reviews or incomplete oversight.
• Absence of SOPs for handling continuing review or protocol amendments.
• Poor documentation practices during IRB meetings.
• Lack of training for IRB members on regulatory requirements.
• Weak sponsor oversight of IRB performance and compliance.

Corrective and Preventive Actions (CAPA)

Corrective Actions

• Conduct retrospective review of protocols and amendments approved late.
• Update TMF with missing IRB approval letters and meeting minutes.
• Retrain IRB members on review timelines and documentation requirements.

Preventive Actions

• Develop SOPs requiring timely review of protocols, amendments, and safety reports.
• Ensure IRBs conduct annual continuing reviews as mandated by regulations.
• Implement electronic systems for tracking IRB submissions, approvals, and reviews.
• Verify IRB compliance through sponsor audits and oversight activities.
• Provide ongoing training for IRB members on evolving regulatory expectations.

Sample IRB Audit Compliance Log

The following dummy table illustrates how IRB compliance can be tracked:

Best Practices for Preventing IRB Audit Findings

To strengthen compliance, sponsors and IRBs should adopt these best practices:

• Maintain inspection-ready documentation of all IRB approvals and reviews in the TMF.
• Conduct regular audits of IRB operations to identify compliance gaps.
• Use electronic tracking systems to monitor review timelines and document submission.
• Provide training and refresher programs for IRB members on evolving regulations.
• Enhance sponsor oversight to ensure IRBs are performing their responsibilities effectively.

Conclusion: Strengthening IRB Oversight in Clinical Trials

IRB audit findings continue to highlight recurring deficiencies in protocol approval, continuing review, and safety oversight. Regulators expect IRBs to maintain timely reviews, thorough documentation, and effective oversight to safeguard participants and ensure compliance.

By implementing SOP-driven processes, electronic tracking, and proactive sponsor oversight, IRBs can minimize audit risks and maintain high standards of ethics and compliance. Effective IRB performance not only ensures regulatory compliance but also reinforces public trust in clinical research.

For additional information, refer to the ISRCTN Registry, which promotes transparency and ethical standards in clinical research oversight.